✦ LIBER ✦

Iron-Based Phosphate Binder PA21: Effective and Well Tolerated in CKD Hemodialysis Patients

Book ID: 114470868
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 257 KB
Volume: 59
Category: Article
ISSN: 0272-6386
DOI: 10.1053/j.ajkd.2012.02.058

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Clinical Trial of the Iron-Ba

Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients

✍ Wuthrich, R. P.; Chonchol, M.; Covic, A.; Gaillard, S.; Chong, E.; Tumlin, J. A. 📂 Article 📅 2012 🏛 American Society of Nephrology 🌐 English ⚖ 643 KB

PA21–A Novel Iron-Based Phosphate Binder

PA21–A Novel Iron-Based Phosphate Binder With a Low Pill Burden: Tolerance in Dialysis Patients

📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Effects of sevelamer and calcium-based p

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

✍ Suki, W N; Zabaneh, R; Cangiano, J L; Reed, J; Fischer, D; Garrett, L; Ling, B N 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 195 KB

PUK1 the Effect of Coadminstration of Ni

PUK1 the Effect of Coadminstration of Nicotinamide and Calcium-Based Phosphate Binder on Hyperphophatemia in Patients Undergoing Hemodialysis

✍ S. Allam; M. El-Hamamsy; M. El Sharkawy 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Effects of Sevelamer and Calcium-Based P

Effects of Sevelamer and Calcium-Based Phosphate Binders on Mortality in Hemodialysis Patients: Results of a Randomized Clinical Trial

✍ Suki, Wadi N. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 435 KB

Effects of sevelamer and calcium-based p

Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial

✍ Jay P. Garg; Scott Chasan-Taber; Andrew Blair; Melissa Plone; Juergen Bommer; Pa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## Objective Gout affects a large fraction of persons with advanced chronic kidney disease, and hyperuricemia may increase the risk of cardiovascular disease. Several hypouricemic agents are contraindicated in patients with end‐stage renal disease. Sevelamer is a nonabsorbed hydrogel t